Clinical Trials | June 03, 2026
Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
While overall survival data remain immature, the results pointed to a favourable trend.
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
The approval is supported by results from the Phase 3 SWOG 1826 trial
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
Subscribe To Our Newsletter & Stay Updated
